News

Merck, known as MSD outside of the United States and Canada, and Harpoon Therapeutics, Inc. announced that the companies have entered into a definitive agreement under which Merck,…
Read More...

Johnson & Johnson announced it has entered into a definitive agreement to acquire Ambrx Biopharma, Inc., or Ambrx, a clinical-stage biopharmaceutical company with a proprietary…
Read More...

Agios Pharmaceuticals, Inc. announced that the global Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia achieved its primary…
Read More...

Esperion Therapeutics, Inc. and Daiichi Sankyo Europe GmbH (DSE) the European headquarter organization of the Japanese pharmaceutical company Daiichi Sankyo Co., Ltd. announced today a…
Read More...

Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Medivir's licensee, Tango…
Read More...

Beijing Avistone Biotechnology Co., Ltd. (also referred to as Avistone Biotechnology or Avistone), an innovative biotechnology company focused on precision oncology therapeutics,…
Read More...

Boehringer Ingelheim and 3T Biosciences (“3T”) announced they have entered into a new strategic collaboration and licensing agreement focused on discovering and developing…
Read More...

Innate Pharma SA announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold placed on the lacutamab IND. On October 5, Innate announced that the…
Read More...

Oragenics, Inc. announces it has completed its previously announced acquisition of assets related to Odyssey Health, Inc.’s proprietary neurological drug therapies and technologies.…
Read More...

AstraZeneca and Sanofi’s Beyfortus (nirsevimab), a long-acting monoclonal antibody, has been approved in China for the prevention of respiratory syncytial virus (RSV) lower respiratory…
Read More...

ImmunityBio, Inc., a clinical-stage immunotherapy company announced an up to $320 million royalty financing and equity investment in the Company by Oberland Capital, with $210 million…
Read More...

MediLink Therapeutics ("MediLink"), announced that it has entered into a worldwide collaboration and license agreement with Roche on the development of a next-generation antibody-drug…
Read More...

Bristol Myers Squibb announced that the European Medicines Agency (EMA) has validated its marketing authorization application for the next-generation tyrosine kinase inhibitor (TKI)…
Read More...

Elpiscience Biopharma, Ltd. and Astellas Pharma Inc. announced a research collaboration and license agreement for novel bi-specific macrophage engagers, ES019 and another program. The…
Read More...

GSK plc and Hansoh Pharma, a Chinese biopharmaceutical company committed to discovering and developing life-changing medicines to help patients conquer serious diseases and disorders,…
Read More...

Ocelot Bio, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics to treat complications of end-stage liver disease (ESLD), announced…
Read More...

Calliditas Therapeutics AB announced that the U.S. Food and Drug Administration (FDA) has approved TARPEYO (budesonide) delayed release capsules to reduce the loss of kidney…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) has accepted, under Priority Review, the company’s supplemental Biologics License Application (sBLA) for Xolair…
Read More...

Merck, known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a new Biologics License Application…
Read More...

Gilead Sciences, Inc. announced an agreement with Compugen Ltd., a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, headquartered in Holon,…
Read More...